Genmab — Juni 2016
-
En tanke: Lad os antage at Genmabs nuværende kurs afspejler forventninger til de nuværende Darzalex godkendelser. Hvis Darzalex i 2017 bliver godkendt til firstline behandling, så forventes patientgrundlaget at mange dobles, måske med en faktor 5-10. Vil det så være rimelig at sige at kursen bør stige 5-10 gange også?
-
Danskerne på køb. A/B på salg. Det ligner noget vi har set før efter store fald efterfulgt af stigning. Om det er en "død kat" ved vi ikke, men muligheden er stor.
-
+3,29%
-
http://www.investopedia.com/terms/d/deadcatbounce.asp du kan læse det her nick.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind